Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct;26(5):e665-e681.
doi: 10.3747/co.26.5193. Epub 2019 Oct 1.

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2018

A J Hyde  1 , R Nassabein  2 , A AlShareef  1 , D Armstrong  3 , S Babak  1 , S Berry  1 , D Bossé  1 , E Chen  1 , B Colwell  4 , C Essery  5 , R Goel  1 , R Goodwin  1 , S Gray  6 , N Hammad  1 , A Jeyakuymar  4 , D Jonker  1 , P Karanicolas  1 , N Lamond  4 , R Letourneau  2 , J Michael  6 , N Patil  4 , E Powell  3 , R Ramjeesingh  4 , W Saliba  4 , R Singh  4 , S Snow  4 , T Stuckless  3 , S Tadros  1 , M Tehfé  2 , M Thana  4 , M Thirlwell  2 , M Vickers  1 , K Virik  1 , S Welch  1 , T Asmis  1
Affiliations

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2018

A J Hyde et al. Curr Oncol. 2019 Oct.

Abstract

The annual Eastern Canadian Gastrointestinal Cancer Consensus Conference was held in Halifax, Nova Scotia, 20-22 September 2018. Experts in radiation oncology, medical oncology, surgical oncology, and pathology who are involved in the management of patients with gastrointestinal malignancies participated in presentations and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses multiple topics in the management of pancreatic cancer, pancreatic neuroendocrine tumours, hepatocellular cancer, and rectal and colon cancer, including ■ surgical management of pancreatic adenocarcinoma,■ adjuvant and metastatic systemic therapy options in pancreatic adenocarcinoma,■ the role of radiotherapy in the management of pancreatic adenocarcinoma,■ systemic therapy in pancreatic neuroendocrine tumours,■ updates in systemic therapy for patients with advanced hepatocellular carcinoma,■ optimum duration of adjuvant systemic therapy for colorectal cancer, and■ sequence of therapy in oligometastatic colorectal cancer.

Keywords: Guidelines; chemotherapy; colorectal cancer; hepatocellular carcinoma; pancreatic cancer; pancreatic neuroendocrine tumours; radiation therapy; surgery.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST DISCLOSURES We have read and understood Current Oncology’s policy on disclosing conf licts of interest, and we declare the following interests: DA is a member of advisory boards for Bristol–Myers Squibb, Sanofi, and Shire, and has received grants or honoraria from Celgene and Amgen; TA is a member of advisory boards for Amgen, Apobiologix, Bayer, Eisai, Novartis, Ipsen, Celgene, and Shire, and has received grants or honoraria from Novartis and Ipsen; SB (Berry) is a member of advisory boards for Amgen, Bayer, Servier, and Taiho, and has received grants or honoraria from Amgen; DB has received grants or honoraria from Amgen, AbbVie, AstraZeneca, Bristol–Myers Squibb, Ipsen, and Pfizer; BC is a member of advisory boards for Amgen, Eli Lilly, Taiho, Shire, Celgene, Merck, and Novartis; EC is a member of advisory boards for Taiho and Eisai, and is listed as co-investigator for trials at an institution that has received funding from AstraZeneca, Bristol–Myers Squibb, Boston Biomedical, Merck, and Seattle Genetics; RG (Goodwin) is a member of advisory boards for Ipsen, Novartis, Taiho, and Celgene, and has received funding from Novartis, Ipson, and Pfizer in an unrestricted grant for a tumour bank; SG is a member of advisory boards for Amgen, Ipsen, Merck, Pfizer, and Sanofi, and has received funding from Janssen and Sanofi as honoraria for a talk; PK is a member of advisory boards for Sanofi and is listed as a co-investigator for trials at an institution that has received for grants or honoraria from Baxter and Sanofi; NL is a member of advisory boards for Amgen, Celgene, Genomic Health, Bristol–Myers Squibb, Novartis, and Eisai, and is a member of speaker’s bureaus for Amgen, AstraZeneca, Astellas, Roche, Eisai, Novartis, Celgene, and Bristol–Myers Squibb; JM is a member of advisory boards for Amgen and has received grants or honoraria from Bristol–Myers Squibb for a talk; EP is a member of advisory boards for Amgen and Pfizer and has received grants or honoraria from Roche for travel to a symposium; RR is a member of advisory boards for Celgene, Servier, Eisai, Merck, Bayer, and Eli Lilly, is a member of the speaker’s bureaus for Celgene, Servier, Novartis, and Eli Lilly, and is listed as co-investigator for trials at an institution that has received funding from Merck, Bristol–Myers Squibb, AstraZeneca, and Macrogenetics, and has received grants or honoraria from Essai and Celgene; WS has received grants or honoraria from Genomic Health for a conference presentation; SS is a member of advisory boards for AstraZeneca, Boehringer Ingelheim, Bristol–Myers Squibb, Merck, Roche, Novartis, Shire, Amgen, and Lilly, is listed as coinvestigator for trials at an institution that has received funding from Bristol–Myers Squibb, Novartis, Merck, and AbbVie, and has received grants or honoraria from Amgen and Taiho for travel; MT (Tehfé) is a member of advisory boards for Bristol–Myers Squibb, AstraZeneca, Merck, Eisai, Takeda Celgene, and Taiho, and has received grants or honoraria from Celgene for research; MT (Thirlwell) is a member of an advisory board for Taiho; KV is a member of an advisory board for Amgen and has received grants or honoraria from Roche for travel to European Society for Medical Oncology meetings; SW is a member of an advisory board for Amgen and has received grants or honoraria from Amgen and Ipsen for invited talks. The remaining authors have no conflicts to disclose.

References

    1. Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2017. Toronto, ON: Canadian Cancer Society; 2017.
    1. Evans DB, George B, Tsai S. Non-metastatic pancreatic cancer: resectable borderline resectable, and locally advanced-definitions of increasing importance for the optimal delivery of multimodality therapy. Ann Surg Oncol. 2015;22:3409–13. doi: 10.1245/s10434-015-4649-2. - DOI - PubMed
    1. Dhir M, Zenati MS, Hamad A, et al. folfirinox versus gemcitabine/nab-paclitaxel for neoadjuvant treatment of resectable and borderline resectable pancreatic head adenocarcinoma. Ann Surg Oncol. 2018;25:1896–903. doi: 10.1245/s10434-018-6512-8. - DOI - PubMed
    1. Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the conko-001 randomized trial. JAMA. 2013;310:1473–81. doi: 10.1001/jama.2013.279201. - DOI - PubMed
    1. Neoptolemos JP, Stocken DD, Friess H, et al. on behalf of the European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200–10. doi: 10.1056/NEJMoa032295. - DOI - PubMed

Publication types

LinkOut - more resources